SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2874)6/27/2013 8:33:32 AM
From: Biotech Jim  Read Replies (1) | Respond to of 3202
 
Rick, it sounds like it is the metabolite, but without knowing the structure of GLPG0634 or the structure of the metabolite, hard for me to tell. It could be a metabolite of the metabolite.

I have not done any GLPG patent sleuthing to know any more.

BJ



To: scaram(o)uche who wrote (2874)6/28/2013 7:36:52 PM
From: tommysdad  Read Replies (2) | Respond to of 3202
 
"Are they basically saying that the metabolite is the product?"

Not quite. They're saying that GLPG 0634 is two, two, two drugs in one. And that that is a good thing. Because . . . I lose the thread at that point.

If the tox species make the same metabolite, and there is plenty of coverage, they probably don't have to run tox on the metabolite itself.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News